3-(4-(4-氟苯基)苯基)丙酸甲酯 | 1008744-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-(4-氟苯基)苯基)丙酸甲酯
• 英文名称: methyl 3-(4-(4-fluorophenyl)phenyl)propanoate
• 英文别名: methyl 3-(4'-fluorobiphenyl-4-yl)propanoate；Methyl 3-[4-(4-fluorophenyl)phenyl]propanoate
• CAS: 1008744-50-0
• 化学式: C₁₆H₁₅FO₂
• 分子量: 258.292
• InChiKey: KRULZLPRUOIEPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-(4-氟苯基)苯基)丙酸甲酯 在 水 、 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以100%的产率得到4'-氟-[1,1'-联苯]-4-丙酸
  参考文献：
  名称：

  Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists

  摘要：

  Structure-affinity relationship (SAR) and structure-kinetics relationship (SKR) studies were combined to investigate a series of biphenyl anthranilic acid agonists for the HCA(2) receptor. In total, 27 compounds were synthesized and twelve of them showed higher affinity than nicotinic acid. Two compounds, 6g (IC50 = 75 nM) and 6z (IC50 = 108 nM) showed a longer residence time profile compared to nicotinic acid, exemplified by their kinetic rate index (KRI) values of 1.31 and 1.23, respectively. The SAR study resulted in the novel 2-F, 4-OH derivative (6x) with an IC50 value of 23 nM as the highest affinity HCA(2) agonist of the biphenyl series, although it showed a similar residence time as nicotinic acid. The SAR and SKR data suggest that an early compound selection based on binding kinetics is a promising addition to the lead optimization process. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.02.018
• 作为产物：
  描述：

  methyl (E)-3-(4'-fluoro[1,1'-biphenyl]-4-yl)acrylate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 2.5h， 生成 3-(4-(4-氟苯基)苯基)丙酸甲酯
  参考文献：
  名称：

  WO2008/23336

  摘要：

  公开号：

文献信息

• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Sattigeri Viswajanani J.

  公开号：US20100081610A1

  公开（公告）日：2010-04-01

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，尤其是对映异构体纯的β-羟基羧酸，以及合成该类化合物和含有本发明化合物的制药组合物的相关过程。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺炎炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他以基质金属蛋白酶过度表达和过度活化为特征的炎症性疾病的方法中使用该化合物。
• Matrix metalloproteinase inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2322507A1

  公开（公告）日：2011-05-18

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及作为基质金属蛋白酶抑制剂的β-羟基和氨基取代的羧酸，特别是非对映异构纯的β-羟基羧酸，以及合成本发明化合物的相应工艺和含有本发明化合物的药物组合物。本发明的化合物可用于治疗各种炎症、自身免疫性和过敏性疾病，如治疗哮喘、类风湿性关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病关节炎、牛皮癣、肺纤维化、伤口愈合障碍、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、多发性骨髓瘤、多发性硬化症、多发性硬化症的方法、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、导致再狭窄和缺血性心力衰竭的新内膜增生、中风、肾脏疾病、肿瘤转移，以及其他以基质金属蛋白酶过度表达和过度激活为特征的炎症性疾病。
• PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2074093B1

  公开（公告）日：2012-10-10
• US8507670B2
  申请人：——

  公开号：US8507670B2

  公开（公告）日：2013-08-13
• US8816073B2
  申请人：——

  公开号：US8816073B2

  公开（公告）日：2014-08-26